Primary High-Risk HPV Testing in Clinical Practice

Dr. Warner Huh shares the clinical importance of primary high-risk HPV testing, challenges in integrating co-testing and primary HPV testing in cli...

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Dr. Warner Huh shares the clinical importance of primary high-risk HPV testing, challenges in integrating co-testing and primary HPV testing in clinical practice, as well as why choose one over the other for individual patients.

  • Disclosure of Conflicts of Interest

    Faculty:
    Warner K. Huh, MD
    Margaret Cameron Spain Endowed Chair in Obstetrics and Gynecology
    Professor/Division Director of Obstetrics and Gynecology
    University of Alabama at Birmingham
    Birmingham, Alabama

    Faculty Disclosure:

    Dr. Huh has disclosed that he is a consultant for Roche Molecular Systems and is on the Scientific Advisory Board for Merck (V503).

    Moderator or Host:
    Jennifer Caudle, DO
    Assistant Professor
    Department of Family Medicine at Rowan University-School of Osteopathic Medicine
    Stratford, New Jersey

    Jennifer Caudle, DO has nothing to disclose.

    Reviewers/Planners/Authors:
    • Sean T. Barrett, CHCP has nothing to disclose.
    • Ken Brown has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Jennifer Spear Smith, PhD has nothing to disclose.

  • Target Audience

    This activity is designed to meet the educational needs of obstetricians, gynecologists, primary care physicians, nurse practitioners, physician assistants, and certified nurse midwives.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the underlying data supporting the FDA decision on hrHPV primary testing for cervical cancer screening, and its relationship to current harmonized guidelines
    • Identify and evaluate adoption barriers to hrHPV primary testing for cervical cancer in their medical practice
    • Differentiate when it is appropriate to integrate co-testing and primary hrHPV testing or chose one over the other when managing HPV+ women
    • Decide which high-risk genotypes are important for management
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25  AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be available for immediate download at www.reachmd.com.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Roche Diagnostics.

  • Terms of Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither Omnia Education nor TOPEC recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Omnia Education or TOPEC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instructions

    There are no fees for participating in and receiving CME credit for this activity. During the period May 17, 2016 through May 17, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post-test, and evaluation will have a statement of credit made available immediately.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required
Optional